Table 2 The ranks for GBM drugs in the three evaluation sets generated by our approach and Hoehndorf’s approach
Evaluation drug (set) | Our approach | Hoehndorf’s approach | p-value | |
|---|---|---|---|---|
Approved drugs | Temozolomide | 6.7 % | NA | NA |
| Â | Carmustine | 10.7 % | NA | NA |
| Â | Bevacizumab | 24.4 % | 67.9 % | NA |
Potential drugs (clinical trials) | 7.8 % | 45.4 % | p=0.003 | |
Off-label drugs (post-marketing surveillance) | 15.3 % | 44.2 % | p=0.02 | |
Combination | 9.2 % | 45.6 % | p=0.0003 | |